1747-53-1 Usage
General Description
2,6-Dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid ethyl ester is a chemical compound with the molecular formula C9H12N2O4. It is an ethyl ester derivative of 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid, and is commonly used as an intermediate in the synthesis of pharmaceutical compounds. This chemical is a white to off-white powder that is soluble in organic solvents and has a strong odor. It is primarily used in research and development applications, and has potential applications in the pharmaceutical industry for the synthesis of various drugs and active pharmaceutical ingredients. Additionally, it is important to handle this compound with care as it may be harmful if ingested, inhaled, or absorbed through the skin.
Check Digit Verification of cas no
The CAS Registry Mumber 1747-53-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,7,4 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1747-53:
(6*1)+(5*7)+(4*4)+(3*7)+(2*5)+(1*3)=91
91 % 10 = 1
So 1747-53-1 is a valid CAS Registry Number.
1747-53-1Relevant articles and documents
Synthesis of orotic acid derivatives and their effects on stem cell proliferation
Al-Obaid, Abdulrahman M.,Alfayez, Musaad,Bari, Ahmed,Betz, Richard,Ghadeer, Abdulrahman,Hosten, Eric C.,Mahmood, Amer,Syed, Saeed Ali
, p. 620 - 627 (2020)
-
3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR
-
Page/Page column 10; 11, (2009/04/25)
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.
INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF
-
Page/Page column 90-91, (2008/06/13)
The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates t
